Voyageur Pharmaceuticals Ltd. (TSX-V: VM) (OTC Pink: VYYRF) provided a corporate update on its barium and iodine contrast media development, highlighting advancements in its vertically integrated strategy to secure critical supply chains for diagnostic imaging. The company aims to address growing global demand, projected to rise from US$6.77 billion in 2024 to US$13.86 billion by 2033, according to Research Contrast.
Voyageur is advancing two bankable feasibility studies (BFS): the Voyageur Radiology Iodine & Barium Drug Manufacturing Project and the Bayer Iodine Project. The Frances Creek (FC) barium contrast project, now in the BFS phase, hosts an indicated and inferred mineral resource of 132,000 tonnes of pharmaceutical-grade barium sulfate, with average purity of 98.8% BaSO4, exceeding the 97.5% pharmaceutical grade threshold. Testing details were outlined in a March 4, 2026 news release. The company has completed product development for five Health Canada-approved barium products with Alberta Veterinary Laboratories, generating approximately C$32,000 in initial sales, which will inform the BFS expected in the second half of 2026.
FDA regulatory pathways for barium and iodine contrast media are expected to follow an 18- to 24-month review process, with potential U.S. market entry as early as mid-to-late 2027. Voyageur initiated the FDA approval process in February 2026 via the 505(b)(2) pathway, with the FDA expected to provide pending requirements in Q1 2026. The company plans to advance a generic iodine FDA license in the second half of 2026. For the iodine drug feasibility, Voyageur is integrating the Mueller iodine extraction process with the Streamline iodine drug manufacturing platform, targeting 35 million doses per year, leveraging iodine-rich brine from U.S. oil and gas operations.
The Bayer Iodine Project, supported by a letter of intent signed on December 20, 2024, focuses on completing a BFS. Subject to success, Bayer may provide capital financing under an offtake-linked production financing arrangement, with Voyageur operating the project. All intellectual property remains exclusively owned by Voyageur. The company is engaging a global engineering firm to complete both BFS, positioning Voyageur to become the only vertically integrated manufacturer of barium and iodine contrast media globally, from mineral extraction to finished products.
Voyageur is reviewing financial options to fund capital expenditures for construction, targeting commencement in 2027. The company’s strategy is designed to maximize stakeholder value and ensure secure, affordable supplies for healthcare authorities worldwide.
